Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:56 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

NCT03031730 · National Cancer Institute (NCI) · PHASE1 · terminated · last registry update 2026-02-10 · Multiple myeloma · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

Kind	Quote	Our category	Source
Stated	“Inadequate accrual rate”	Open Targets' class: insufficient enrollment	Registry record, National Cancer Institute (NCI)

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against PSMD1 in multiple myeloma within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

Internal portfolio and board discussions
Unpublished trial data and interim analyses
Terms of any partner or licence decision